329 related articles for article (PubMed ID: 33683917)
1. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
Fowler NH; Samaniego F; Jurczak W; Ghosh N; Derenzini E; Reeves JA; Knopińska-Posłuszny W; Cheah CY; Phillips T; Lech-Maranda E; Cheson BD; Caimi PF; Grosicki S; Leslie LA; Chavez JC; Fonseca G; Babu S; Hodson DJ; Shao SH; Burke JM; Sharman JP; Law JY; Pagel JM; Miskin HP; Sportelli P; O'Connor OA; Weiss MS; Zinzani PL
J Clin Oncol; 2021 May; 39(15):1609-1618. PubMed ID: 33683917
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
Wang Z; Zhou H; Xu J; Wang J; Niu T
Front Immunol; 2022; 13():1070660. PubMed ID: 36685572
[TBL] [Abstract][Full Text] [Related]
3. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Neelapu SS; Chavez JC; Sehgal AR; Epperla N; Ulrickson M; Bachy E; Munshi PN; Casulo C; Maloney DG; de Vos S; Reshef R; Leslie LA; Oluwole OO; Yakoub-Agha I; Khanal R; Rosenblatt J; Korn R; Peng W; Lui C; Wulff J; Shen R; Poddar S; Jung AS; Miao H; Beygi S; Jacobson CA
Blood; 2024 Feb; 143(6):496-506. PubMed ID: 37879047
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma.
Wang H; Feng J; Liu Y; Qian Z; Gao D; Ran X; Zhou H; Liu L; Wang B; Fang M; Zhou H; Huang Z; Tao S; Chen Z; Su L; Su H; Yang Y; Xie X; Wu H; Sun P; Hu G; Liang A; Li Z
Signal Transduct Target Ther; 2024 Apr; 9(1):99. PubMed ID: 38627366
[TBL] [Abstract][Full Text] [Related]
5. Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma.
Bosch F; Kuruvilla J; Vassilakopoulos TP; Maio DD; Wei MC; Zumofen MB; Nastoupil LJ
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):105-121. PubMed ID: 37981564
[TBL] [Abstract][Full Text] [Related]
6. Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.
Budde LE; Assouline S; Sehn LH; Schuster SJ; Yoon SS; Yoon DH; Matasar MJ; Bosch F; Kim WS; Nastoupil LJ; Flinn IW; Shadman M; Diefenbach C; Cheah CY; Ma CY; Huang H; Kwan A; Wei MC; Yin S; Bartlett NL
J Clin Oncol; 2024 Mar; ():JCO2302329. PubMed ID: 38547425
[No Abstract] [Full Text] [Related]
7. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Hutchings M; Morschhauser F; Iacoboni G; Carlo-Stella C; Offner FC; Sureda A; Salles G; Martínez-Lopez J; Crump M; Thomas DN; Morcos PN; Ferlini C; Bröske AE; Belousov A; Bacac M; Dimier N; Carlile DJ; Lundberg L; Perez-Callejo D; Umaña P; Moore T; Weisser M; Dickinson MJ
J Clin Oncol; 2021 Jun; 39(18):1959-1970. PubMed ID: 33739857
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
9. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Matasar MJ; Capra M; Özcan M; Lv F; Li W; Yañez E; Sapunarova K; Lin T; Jin J; Jurczak W; Hamed A; Wang MC; Baker R; Bondarenko I; Zhang Q; Feng J; Geissler K; Lazaroiu M; Saydam G; Szomor Á; Bouabdallah K; Galiulin R; Uchida T; Soler LM; Cao A; Hiemeyer F; Mehra A; Childs BH; Shi Y; Zinzani PL
Lancet Oncol; 2021 May; 22(5):678-689. PubMed ID: 33848462
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of follicular lymphoma: genetics to the microenvironment to clinical translation.
Kumar E; Pickard L; Okosun J
Br J Haematol; 2021 Sep; 194(5):810-821. PubMed ID: 33694181
[TBL] [Abstract][Full Text] [Related]
11. Umbralisib: First Approval.
Dhillon S; Keam SJ
Drugs; 2021 May; 81(7):857-866. PubMed ID: 33797740
[TBL] [Abstract][Full Text] [Related]
12. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Caimi PF; Ai W; Alderuccio JP; Ardeshna KM; Hamadani M; Hess B; Kahl BS; Radford J; Solh M; Stathis A; Zinzani PL; Havenith K; Feingold J; He S; Qin Y; Ungar D; Zhang X; Carlo-Stella C
Lancet Oncol; 2021 Jun; 22(6):790-800. PubMed ID: 33989558
[TBL] [Abstract][Full Text] [Related]
13. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.
Julia E; Salles G
Future Oncol; 2021 Jun; 17(17):2127-2140. PubMed ID: 33709777
[TBL] [Abstract][Full Text] [Related]
14. Characterization of DLBCL with a PMBL gene expression signature.
Duns G; Viganò E; Ennishi D; Sarkozy C; Hung SS; Chavez E; Takata K; Rushton C; Jiang A; Ben-Neriah S; Woolcock BW; Slack GW; Hsi ED; Craig JW; Hilton LK; Shah SP; Farinha P; Mottok A; Gascoyne RD; Morin RD; Savage KJ; Scott DW; Steidl C
Blood; 2021 Jul; 138(2):136-148. PubMed ID: 33684939
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma.
Barraclough A; Bishton M; Cheah CY; Villa D; Hawkes EA
Br J Haematol; 2021 Oct; 195(1):15-24. PubMed ID: 33704790
[TBL] [Abstract][Full Text] [Related]
16. Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma.
Haebe S; Shree T; Sathe A; Day G; Czerwinski DK; Grimes SM; Lee H; Binkley MS; Long SR; Martin B; Ji HP; Levy R
Blood; 2021 May; 137(21):2869-2880. PubMed ID: 33728464
[TBL] [Abstract][Full Text] [Related]
17. Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.
Murali I; Kasar S; Naeem A; Tyekucheva S; Khalsa JK; Thrash EM; Itchaki G; Livitz D; Leshchiner I; Dong S; Fernandes SM; Getz G; Johnson A; Brown JR
Blood; 2021 Jul; 138(1):44-56. PubMed ID: 33684943
[TBL] [Abstract][Full Text] [Related]
18. Acalabrutinib in treatment-naive chronic lymphocytic leukemia.
Byrd JC; Woyach JA; Furman RR; Martin P; O'Brien S; Brown JR; Stephens DM; Barrientos JC; Devereux S; Hillmen P; Pagel JM; Hamdy A; Izumi R; Patel P; Wang MH; Jain N; Wierda WG
Blood; 2021 Jun; 137(24):3327-3338. PubMed ID: 33786588
[TBL] [Abstract][Full Text] [Related]
19. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma.
Ma MCJ; Tadros S; Bouska A; Heavican T; Yang H; Deng Q; Moore D; Akhter A; Hartert K; Jain N; Showell J; Ghosh S; Street L; Davidson M; Carey C; Tobin J; Perumal D; Vose JM; Lunning MA; Sohani AR; Chen BJ; Buckley S; Nastoupil LJ; Davis RE; Westin JR; Fowler NH; Parekh S; Gandhi M; Neelapu S; Stewart D; Bhalla K; Iqbal J; Greiner T; Rodig SJ; Mansoor A; Green MR
Haematologica; 2022 Mar; 107(3):690-701. PubMed ID: 33792219
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia.
Rogers KA; Andritsos LA; Wei L; McLaughlin EM; Ruppert AS; Anghelina M; Blachly JS; Call T; Chihara D; Dauki A; Guo L; Ivy SP; James LR; Jones D; Kreitman RJ; Lozanski G; Lucas DM; Ngankeu A; Phelps M; Ravandi F; Schiffer CA; Carson WE; Jones JA; Grever MR
Blood; 2021 Jun; 137(25):3473-3483. PubMed ID: 33754642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
